VCAM1 and B-cell chronic lymphocytic leukemia: Consequently,BCR triggering results in enhanced integrin-mediated B cell adhesion, which, inturn, can be reversed via PI3Kδ inhibition with idelalisib, inhibitingintegrin-mediated adhesion of CLL B cells to VCAM1 (CD106) (Fiorcari et al.2013).